Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs

References

• Teras LR, DeSantis CE, Cerhan JR, et al. US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–459.
   PubMed Web of Science ®Google Scholar
• Geynisman DM, Wickersham KE. Adherence to targeted oral anticancer medications. Discov Med. 2013;15:231–241.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Williams ME. Oral Therapies in Lymphoma: Opportunities and Challenges in Research and Treatment. A Lymphoma Research Foundation White Paper: Lymphoma Research Foundation; 2015.
   Google Scholar
• Friedberg JW, Williams ME. Adherence and Oral Therapies in Lymphoma and CLL. A Lymphoma Research Foundation White Paper: Lymphoma Research Foundation; 2018.
   Google Scholar
• Valla K, Flowers CR, Koff JL. Targeting the B cell receptor pathway in non-Hodgkin lymphoma. Exp Opin Invest Drugs. 2018;6:513–522.
   PubMed Web of Science ®Google Scholar
• Tam CS, Simpson D, Opat S, et al. Safety and activity of the highly specific BTK inhibitor BGB-3111 in patients with indolent and aggressive non-Hodgkin's lymphoma. Blood. 2017;130:152–152.
   Web of Science ®Google Scholar
• FDA. Duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) www.fda.gov: U.S. Food & Drug Administration; 2018 [cited 2018 Nov 21]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621503.htm
   Google Scholar
• Sharman J, Hawkins M, Kolibaba K, et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015;125:2336–2343.
   PubMed Web of Science ®Google Scholar
• Burke JM, Shustov A, Essell J, et al. An open-label, phase II trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18:e327–e331.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33:2803–2811.
   PubMed Web of Science ®Google Scholar
• Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27:1902–1909.
   PubMed Web of Science ®Google Scholar
• FDA. Hematology/oncology (cancer) approvals & safety notifications. Silver Spring (MD): U.S. Food & Drug Administration; 2018 [cited 2019 Mar 22]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm.
   Google Scholar
• Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379:934–947.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Trněný M, Izutsu K, et al. A phase III randomized study of lenalidomide plus rituximab (R2) vs rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma. 2018.
   Google Scholar
• Cang S, Iragavarapu C, Savooji J, et al. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol. 2015;8:129.
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine. Selinexor in initial or relapsed/refractory Richter’s transformation. ClinicalTrials.gov: U.S. National Library of Medicine; 2018 [cited 2019 Mar 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT02138786
   Google Scholar
• US National Library of Medicine. A phase 2b open-label study of selinexor (KPT-330) in patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). ClinicalTrials.gov: U.S. National Library of Medicine; 2018 [cited 2019 Mar 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT02227251
   Google Scholar
• Crump M, Leppä S, Fayad L, et al. Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma. J Clin Oncol. 2016;34:2484–2492.
   PubMed Web of Science ®Google Scholar
• Evens AM, Balasubramanian S, Vose JM, et al. A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lymphoma. Clin Cancer Res. 2016;22:1059–1066.
   PubMed Web of Science ®Google Scholar
• Halfdanarson TR, Jatoi A. Oral cancer chemotherapy: the critical interplay between patient education and patient safety. Curr Oncol Rep. 2010;12:247–252.
   PubMed Web of Science ®Google Scholar
• Eek D, Krohe M, Mazar I, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609–1621.
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381–2388.
   PubMed Web of Science ®Google Scholar
• Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401–5411.
   PubMed Web of Science ®Google Scholar
• Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129:2612–2615.
   PubMed Web of Science ®Google Scholar
• Sabaté E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.
   Google Scholar
• Alrabiah Z, Alhossan A, Yun S, et al. Adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia: meta-analyses of prevalence rates by measurement method. Blood. 2016;128:3610–3610.
   Google Scholar
• Gater A, Heron L, Abetz-Webb L, et al. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res. 2012;36:817–825.
   PubMed Web of Science ®Google Scholar
• Williams AB, Amico KR, Bova C, et al. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17:284–297.
   PubMed Web of Science ®Google Scholar
• Geissler J, Sharf G, Bombaci F, et al. Factors influencing adherence in CML and ways to improvement: results of a patient-driven survey of 2546 patients in 63 countries. J Cancer Res Clin Oncol. 2017;143:1167–1176.
   PubMed Web of Science ®Google Scholar
• Aitken M, Kleinrock M. Global Oncology Trend Report: A Review of 2015 and Outlook to 2020. IMS Institute for Healthcare Informatics; 2016.
   Google Scholar
• Chen Q, Jain N, Ayer T, et al. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017;35:166–174.
   PubMed Web of Science ®Google Scholar
• Zafar SY, Abernethy AP. Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park). 2013;27:80–81, 149.
   PubMed Web of Science ®Google Scholar
• Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013;18:381–390.
   PubMed Web of Science ®Google Scholar
• Dusetzina SB, Winn AN, Abel GA, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32:306–311.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin. 2010;26:61–69.
   PubMed Web of Science ®Google Scholar
• Liewer S, Huddleston AN. Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients. Expert Rev Anticancer Ther. 2015;15:453–464.
   PubMed Web of Science ®Google Scholar
• Levine AM, Richardson JL, Marks G, et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol. 1987;5:1469–1476.
   PubMed Web of Science ®Google Scholar
• Lee CR, Nicholson PW, Souhami RL, et al. Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol. 1992;10:1007–1013.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Nowakowski GS, Habermann TM, et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol. 2015;26:1667–1677.
   PubMed Web of Science ®Google Scholar
• Brown JR. How I treat CLL patients with ibrutinib. Blood. 2018;131:379–386.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–1018.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019;11:912–922.
   Web of Science ®Google Scholar
• Pereira-Salgado A, Westwood JA, Russell L, et al. Mobile health intervention to increase oral cancer therapy adherence in patients with chronic myeloid leukemia (The REMIND System): clinical feasibility and acceptability assessment. JMIR Mhealth Uhealth. 2017;5:e184.
   PubMed Web of Science ®Google Scholar
• Muluneh B, Schneider M, Faso A, et al. Improved adherence rates and clinical outcomes of an integrated, closed-loop, pharmacist-led oral chemotherapy management program. J Oncol Pract. 2018;14:e324–e334.
   PubMed Web of Science ®Google Scholar
• Lam MS, Cheung N. Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia. J Oncol Pharm Pract. 2016;22:741–748.
   PubMed Web of Science ®Google Scholar
• Guérin A, Chen L, Dea K, et al. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin. 2014;30:1345–1352.
   PubMed Web of Science ®Google Scholar
• Richardson JL, Shelton DR, Krailo M, et al. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol. 1990;8:356–364.
   PubMed Web of Science ®Google Scholar
• Curry MA, Redelico T, Terrell C, et al. Adherence to oral anticancer medications after implementation of an ambulatory adherence program at a large urban academic hospital. J Clin Oncol. 2018;36:6591.
   Web of Science ®Google Scholar
• Tamaroff MH, Festa RS, Adesman AR, et al. Therapeutic adherence to oral medication regimens by adolescents with cancer. II. Clinical and psychologic correlates. J Pediatr. 1992;120:812–817.
   PubMed Web of Science ®Google Scholar
• Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25:481–496.
   PubMed Web of Science ®Google Scholar